Targeting a specific type of kidney cancer with new therapies
Therapeutic targeting of VHL-deficient clear cell renal cell carcinoma
['FUNDING_R21'] · UNIVERSITY OF CALIFORNIA-IRVINE · NIH-11003694
This study is looking for new ways to treat clear cell kidney cancer by testing special drugs that could help target cancer cells with a specific mutation, aiming to offer better options for patients who are facing this tough condition.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA-IRVINE (nih funded) |
| Locations | 1 site (IRVINE, UNITED STATES) |
| Trial ID | NIH-11003694 on ClinicalTrials.gov |
What this research studies
This research focuses on developing new treatments for clear cell renal cell carcinoma (ccRCC), a type of kidney cancer that often resists current therapies. The approach utilizes synthetic lethality screens to identify compounds that can selectively kill cancer cells with a specific mutation while sparing normal cells. The study aims to investigate the effectiveness of cyclin-dependent kinase (CDK) inhibitors, particularly CDK9 inhibitors, in targeting VHL-deficient ccRCCs. If successful, these therapies could lead to improved treatment options for patients with this challenging cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with VHL-deficient clear cell renal cell carcinoma who have not responded well to existing therapies.
Not a fit: Patients with other types of kidney cancer or those whose tumors do not have VHL mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide more effective treatment options for patients with VHL-deficient clear cell renal cell carcinoma.
How similar studies have performed: Other research has shown promise in using synthetic lethality approaches for cancer treatment, indicating potential success for this novel strategy.
Where this research is happening
IRVINE, UNITED STATES
- UNIVERSITY OF CALIFORNIA-IRVINE — IRVINE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: RAZORENOVA, OLGA V — UNIVERSITY OF CALIFORNIA-IRVINE
- Study coordinator: RAZORENOVA, OLGA V
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy